Article Text

Download PDFPDF
Enhancement of Ovarian Tumor Detection by DR6-Targeted Ultrasound Imaging Agents in Laying Hen Model of Spontaneous Ovarian Cancer
  1. Animesh Barua, PhD,
  2. Seby L. Edassery, MS,
  3. Sa’Rah McNeal, MS,
  4. Janice M. Bahr, PhD,
  5. Pincas Bitterman, MD,
  6. Sanjib Basu, PhD,
  7. Sameer Sharma, MD and
  8. Jacques S. Abramowicz, MD
  1. * Departments of Pharmacology,
  2. Obstetrics and Gynecology, and
  3. Pathology, Rush University Medical Center, Chicago;
  4. § Department of Animal Sciences, University of Illinois at Urbana-Champaign, Urbana;
  5. Department of Preventive Medicine (Biostatistics), Rush University Medical Center, Chicago, IL; and
  6. Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI.
  1. Address correspondence and reprint requests to Animesh Barua, PhD, Laboratory for Translational Research on Ovarian Cancer, Department of Pharmacology, Room # 410, Cohn Building, Rush University Medical Center, 1735 W Harrison St, Chicago, IL 60612. E-mail: Animesh_Barua{at}


Objective The lack of an effective early detection test leads to high case to death ratio of women with ovarian cancer (OVCA). To improve early detection, tumor-associated imaging targets need to be established and imaging agents to image these targets need to be developed. Targeted imaging agents offer potential for improvement of signal intensities from their targets. Expression of death receptor 6 (DR6) by ovarian malignant cells and tumor-associated microvessels increases during OVCA development and represents a novel target for ultrasound imaging. The goal of this study was to examine the feasibility of newly developed DR6-targeted ultrasound imaging agents in enhancing early detection of ovarian tumors in laying hen model of spontaneous OVCA.

Materials and Methods The study was conducted in an exploratory cross-sectional design using 4-year-old laying hens (n = 130). DR6-targeted imaging agents were developed by conjugating microbubbles with rabbit anti-chicken DR6 antibodies. Changes in signal intensity of ultrasound imaging were determined before and after injection of targeted imaging agents in hens with or without spontaneous OVCA. Following targeted imaging, normal or tumor ovaries were processed for histopathological and immunohistochemical studies.

Results DR6-targeted imaging agents bound with their targets expressed by malignant cells and tumor-associated microvessels in the ovary. Compared with pretargeted imaging, targeted imaging is enhanced by approximately 40% ultrasound echo signal intensity (P < 0.001) from early- and late-stage OVCA. Differences in signal enhancement were not observed among different histological subtypes of OVCA at early or late stages. Higher imaging signal intensities were associated with enhancement in DR6 expression by ovarian malignant cells and increase in the frequency of DR6-expressing microvessels during OVCA development.

Conclusions The results of this study suggest that DR6-targeted imaging agents enhance the visualization of ovarian tumors and tumor-associated microvessels in hens with early-stage OVCA and will form a foundation for clinical studies.

  • Ovarian cancer
  • Early detection
  • Targeted-imaging
  • Death receptor 6
  • Animal model

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.